Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 2/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL666996 | 0.92 | HCRTR2 (0.48) | HCRTR2ACACBMEN1KMT2AHPGDS | |
| SCHEMBL667753 | 0.91 | HCRTR2 (0.41) | HCRTR2ACACBLRRK2MAPK1HPGDS | |
| SCHEMBL667392 | 0.90 | KCNK3 (0.41) | MAPK1HPGDSCNR2PDE2A | |
| SCHEMBL666604 | 0.90 | HCRTR2 (0.40) | HCRTR2MEN1KMT2AHPGDSCNR2 | |
| SCHEMBL667251 | 0.85 | CNR2 (0.42) | ACACBMAPK1HPGDSCNR2MET | |
| SCHEMBL668319 | 0.83 | HCRTR2 (0.45) | HCRTR2ACACBMAPK1HPGDSCNR2 | |
| SCHEMBL10166866 | 0.82 | HCRTR2 (0.58) | HCRTR2 | |
| SCHEMBL666511 | 0.82 | LRRK2 (0.44) | MEN1KMT2ALRRK2CNR2PTGER4 | |
| SCHEMBL666458 | 0.81 | KDM4E (0.40) | HCRTR2ACACBMAPK1HPGDSPDE2A | |
| SCHEMBL10166441 | 0.74 | HCRTR2 (0.58) | HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703770-B2 | Pyridazine carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-04-22 | — | — | US | claimed |
| US-20120046289-A1 | Pyridazine Carboxamide Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2012-02-23 | — | — | US | claimed |
| EP-2349267-B1 | PYRIDAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8703770-B2 | Pyridazine carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703770-B2 | Pyridazine carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703770-B2 | Pyridazine carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20120046289-A1 | Pyridazine Carboxamide Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2012-02-23 | — | — | US | disclosed |
| US-20120046289-A1 | Pyridazine Carboxamide Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2012-02-23 | — | — | US | disclosed |
| WO-2010051238-A1 | PYRIDAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046289-A1 | Pyridazine Carboxamide Orexin Receptor Antagonists | HCRTR2, HCRTR1, NPY5R | HCRTR2 1/4885ACACB 3194/4885MEN1 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.